TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
9.97
+1.39 (16.20%)
At close: Feb 5, 2026, 4:00 PM EST
9.54
-0.43 (-4.31%)
After-hours: Feb 5, 2026, 5:14 PM EST

TransCode Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
2.845.812.774.9720.830.83
Short-Term Investments
---0.010.010
Cash & Short-Term Investments
2.845.812.774.9820.840.83
Cash Growth
51.18%109.97%-44.40%-76.11%2406.60%306.52%
Prepaid Expenses
0.480.340.551.381.46-
Other Current Assets
1.240.941.141.020.44-
Total Current Assets
4.757.094.467.3822.730.83
Property, Plant & Equipment
0.020.090.60.210.21-
Long-Term Deferred Charges
0.46----0.22
Other Long-Term Assets
-0.110.11---
Total Assets
5.237.295.177.5922.941.06
Accrued Expenses
2.972.713.054.352.50.4
Current Portion of Leases
-0.040.41---
Current Unearned Revenue
-0.030.03-0.03-
Total Current Liabilities
2.972.773.494.352.530.4
Long-Term Debt
-----2.09
Long-Term Leases
--0.04---
Other Long-Term Liabilities
0.836.54---1.97
Total Liabilities
3.89.313.534.352.534.46
Common Stock
000000
Additional Paid-In Capital
85.8561.1848.0631.1130.710.07
Retained Earnings
-84.42-63.2-46.42-27.87-10.31-3.46
Comprehensive Income & Other
------0.01
Shareholders' Equity
1.43-2.021.643.2420.4-3.41
Total Liabilities & Equity
5.237.295.177.5922.941.06
Total Debt
-0.040.45--2.09
Net Cash (Debt)
2.845.772.324.9820.84-1.26
Net Cash Growth
64.55%149.15%-53.45%-76.11%--
Net Cash Per Share
6.07453.91----
Filing Date Shares Outstanding
0.920.83----
Total Common Shares Outstanding
0.830.04----
Working Capital
1.784.320.963.0320.20.43
Book Value Per Share
1.71-54.93----
Tangible Book Value
1.43-2.021.643.2420.4-3.41
Tangible Book Value Per Share
1.71-54.93----
Machinery
0.360.360.380.350.25-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q